Skip to main content
Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze 6661 威健生技. Please read: https://finlab.finance/en/setup?stock=6661

No install, open FinLab Studio

6661

威健生技 Biotech & Healthcare As of 2026-06-17 Updated daily after market close

quality needs a look, premium valuation.

1 active signal
Revenue ≥20%
This page refreshes daily after the close. Add 威健生技 to your watchlist to track signal changes on your next visit.
Valuation 28Quality 14Growth 76Momentum 12Chips 27

Is 威健生技 a buy? Fundamentals and valuation first

  • Weak profitability.Operating margin is in the 17th market percentile. Latest quarterly ROE ≈ -2.1%.

  • Valuation is high.PE is in the 97th market percentile; within its own history, PE is around the 92th percentile.

  • Foreign investors are net selling.Foreign 20-day net flow ≈ -1.5% of volume (net sell).

  • Strong revenue growth.Latest monthly revenue YoY ≈ 33.4%, above the 20% growth threshold.

  • Signals are active now.On the latest data, signals such as Revenue YoY ≥ 20% are active — see the historical forward returns after each occurrence below.

Chip flow

Bullish +0.62
BearishNeutralBullish

Single-sided accumulation, concentration rising — bullish

  • Single-sided accumulation, concentration rising — bullish
  • 華南永昌-敦南 holds 166 lots
  • sellers have 0 lots left

Window from 2026-01-17 · Price -15% · branches to 2026-06-17· TDCC to 2026-06-12

  • Largest holder 華南永昌-敦南 has accumulated 166 lots since the start (sold 0%), still adding.
  • Main distributor 華南永昌-彰化 peaked at 10 lots, has sold 70%, 3 left, paused recently.
  • TDCC big holders (absolute) >1000-lot holders +0.68pp, mid holders +0, retail -0.69pp — concentration shifting upward.
  • Foreign hedge-desk net short Net short -26 lots (inferred from branch profile, mostly hedging — not necessarily bearish, not case-confirmed).
Branch inventory reconstruction
Accumulating holders Branches that accumulated shares during the window and still hold positive inventory; they are the absorbing side.
Distributing sellers Branches that built inventory earlier and have been selling it down; the remaining number estimates what has not cleared.
Net-short desks Trading-desk branches with negative inventory or net selling, often hedge, offsetting, or short-term flow. It is not automatically a bearish view.
Accumulating
華南永昌-敦南玉山-台南致和證券永豐金-天母中國信託-嘉義元大-古亭
Distributing
華南永昌-彰化台新-花蓮凱基-站前台新
Desks
own scale
華南永昌-林口富邦-新營土銀-高雄合庫-彰化
Price Accumulating & Distributing share one scale (comparable); Desks is independent. Zero is the baseline
Branch details Unit: lots

Accumulating

  • 華南永昌-敦南 +166
    sold 0%· still adding
  • 玉山-台南 +54
    sold 0%
  • 致和證券 +36
    sold 0%· still adding
  • 永豐金-天母 +19
    sold 0%· still adding
  • 中國信託-嘉義 +15
    sold 0%· still adding
  • 元大-古亭 +12
    sold 0%

Distributing

  • 華南永昌-彰化 3 left
    sold 70%· paused recently
  • 台新-花蓮 2 left
    sold 33%· paused recently
  • 凱基-站前 1 left
    sold 50%· paused recently
  • 台新 1 left
    sold 50%· paused recently

Desks

  • 華南永昌-林口 -59
    unclassified
  • 富邦-新營 -26
    unclassified
  • 土銀-高雄 -22
    unclassified
  • 合庫-彰化 -15
    unclassified
Still selling 0 lots
Recent buy/sell force +79 absorbed / 0 sold buyers slightly ahead
TDCC big holders · absolute-holding cross-check
>1000-lot holder share Retail (<400 lots) share Price (right axis)

Direction matches: big-holder share rose while retail share fell.

Describes chip flow, not investment advice. Branch data discloses only high-volume branches with ~1-day lag; TDCC is weekly. Inventory is a relative reconstruction from the window start, not absolute holdings.

Historical evidence

Signals active now

These signals are true on the latest data, with this stock's own historical forward-return stats after each occurrence.

Monthly revenue YoY ≥ 20% (from filing deadline)

Active · now 33.4%

Monthly revenue YoY ≥ 20%; event date is the first trading day after the filing deadline (no look-ahead).

38 historical occurrences (since 2021-01-27)
Average forward return after Monthly revenue YoY ≥ 20% (from filing deadline)。20-day: Win 21.1%, Sample 19, Median -1.95%, Excess -3.83%, Beat mkt rate 15.8%；60-day: Win 27.8%, Sample 18, Median -3.32%, Excess -9.29%, Beat mkt rate 22.2%；120-day: Win 29.4%, Sample 17, Median -6.25%, Excess -16.77%, Beat mkt rate 29.4%

120 days after: historical avg -3.26%

20-day -1.8%
60-day -4.26%
120-day -3.26%
20-day
60-day
120-day
Win
21.1%
27.8%
29.4%
Sample
19
18
17
Median
-1.95%
-3.32%
-6.25%
Excess
-3.83%
-9.29%
-16.77%
Beat mkt rate
15.8%
22.2%
29.4%

Over 17 occurrences, 120-day forward avg declined 3.26%, lagged the market by 16.77 pts; win rate 29.4%.

Valuation regime and subsequent returns

Each day's PE is converted to its own-history percentile (as of that day), then we look at adjusted-close returns over the next 240 trading days by valuation regime.

PE percentile bandSample days240-day avg returnMedianWin rateAvg excess (vs index)
0-20 0Insufficient data
20-40 0Insufficient data
40-60 0Insufficient data
60-80 0Insufficient data
80-100 You are here0Insufficient data

Percentiles use an expanding own-history window (no look-ahead); forward return is 240 trading days on adjusted close. Sample days overlap; distribution is indicative only.

Current PE ≈ 294.17, at the 91.5th percentile of its own history (80-100 band).

Valuation × momentum historical grid

Every day in its own history is bucketed by valuation tercile (own-history PE) and 60-day momentum sign into six cells; we show adjusted-close returns over the next 120 trading days per cell.

Valuation
Momentum
Cheap (own-history bottom 1/3)
Mid
Expensive (own-history top 1/3)
60-day momentum up
Insufficient data
(0d)
Insufficient data
(0d)
-13.2%
Win rate 0% Excess -45.8%
37d
60-day momentum down
Insufficient data
(0d)
Insufficient data
(0d)
Now
-6.5%
Win rate 2.1% Excess -44.8%
48d

Currently in “Expensive (own-history top 1/3) × 60-day momentum down”: across 48 historical days, 120-day forward avg declined 6.5%, win rate 2.1%, lagged the market by 44.8%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Does this signal hold up across the market

Over the past 242 months, on average ~404 stocks per month met “monthly revenue YoY ≥ 20%”; their adjusted-close return over the next 60 trading days averaged 6.94% (equal-weighted), beating the market by 2.37 points on average, and outperformed the TAIEX total-return index in 64.5% of months.

Each month, equal-weighted 60-day forward adjusted return of all signal-matching stocks, then averaged across months; excess vs the TAIEX total-return index.

Signals not active (historical stats for reference)

These are not occurring now; historical samples shown for comparison.

252-day price high (breakout)

Pending

Adjusted close makes a new 252-day high; repeats within 20 days counted once.

Foreign net buying for 5 straight days

Pending

Foreign net flow (ex-dealer) positive for 5 straight days; event on day 5; repeats within 20 days counted once.

What does 威健生技 do? Company profile

生技醫療業 上櫃

Overview

6661 對應證券為威健股份有限公司，市場別為櫃買中心上櫃，證券類型為普通股。公司成立於 2003-01-30，總部位於台北市南港區園區街 3 號 12 樓，統一編號 80158777，2021-01-27 上櫃。董事長為陳貴弘，總經理為林怡杏，發言人為陳盈任。公開資料顯示實收資本額為新台幣 233,042,480 元，已發行普通股 23,304,248 股。依 113 年年報截至 2025-04-30 從業員工 96 人，其中銷售 40 人、管理 19 人、研發及技術 10 人、測試 27 人；平均年齡 40.71 歲、平均服務年資 8.08 年。主要股東依 113 年年報截至 2025-04-30 包括漢碁股份有限公司 30.31%、漢津股份有限公司 9.95%、漢衢股份有限公司 9.93%、申碁股份有限公司 8.02%、陳貴弘 2.10%、陳貴正 2.10%、維雲投資有限公司 1.41%、林怡杏 1.40%、林家綺 1.25%、周佳宏 1.09%、鉅富霖有限公司 1.00%。公司長期聚焦高通量基因檢測技術，包括基因晶片、次世代定序、即時定量 PCR、第三代定序、生物資訊分析，並整合代理試劑、儀器與檢測服務。子公司/轉投資包括威茂股份有限公司（100%）與微傳股份有限公司（83%）。

Business

威健生技主要商業模式是以科研服務與臨床應用雙軸營運：一方面對學術研究機構、醫學研究單位、產業客戶提供基因晶片、NGS、第三代定序、全外顯子定序、菌相分析、蛋白質體檢測、生物資訊分析與實驗流程設計；另一方面將科研平台轉化為產前、生殖醫學、遺傳疾病與癌症相關臨床檢測服務。臨床產品包含產前羊水晶片、胚胎著床前染色體篩檢、非侵入性胎兒染色體檢測、遺傳疾病全外顯子定序、EndoPredict 乳癌復發/轉移風險評估、Guardant360 液態活檢癌症基因檢測與 Guardant360 TissueNext 腫瘤組織癌症基因檢測。代理銷售端包括 Agilent Technologies 生物晶片、NGS、CRISPR、定量 PCR 相關產品，Guardant Health 癌症液態活檢產品，Epigentek 檢測套組與抗體，SomaLogic 蛋白質體平台等。依 114 年度年報彙整資料，114 年營收 375,940 仟元、營業毛利 156,179 仟元、稅後淨利 1,296 仟元；產品營收結構為試劑銷售收入 142,117 仟元、37.80%，基因檢測收入 123,236 仟元、32.78%，癌症液態活檢檢測收入 73,768 仟元、19.62%，儀器銷售收入 35,515 仟元、9.45%，其他營業收入 1,304 仟元、0.35%。依 113 年報，113 年營收結構為試劑銷售 40.39%、基因檢測 39.52%、儀器銷售 17.51%、癌症液態活檢 2.39%、其他 0.19%。2026 年 5 月營收公開資訊顯示單月合併營收 43,136 仟元、年增 33.41%；2025 全年累計營收 375,654 仟元、年增 16.46%。主要客戶未揭露單一客戶名稱，年報顯示最近二年度無單一銷貨客戶占比超過 10%，下游以醫學中心、醫療院所、生殖醫學中心、學術研究機構、研究單位與產業研發客戶為主。

Outlook 2025–2028

2025 至 2028 年展望重點在精準醫療、多體學整合與癌症早篩市場滲透。成長動能包括：一、Guardant Health 液態活檢產品自晚期癌症基因檢測延伸至早期癌症篩檢與監測，若能順利導入醫療院所並取得醫師與自費/補助市場採用，潛在客群將由利基晚癌族群擴大至亞健康與健康篩檢族群。二、公司導入 SomaLogic 蛋白質體技術，目標建立在地化服務與原廠認證，結合基因體、轉錄體與蛋白質體，提升科研服務與疾病生物標記開發能力。三、第三代定序平台已取得 TAF ISO 認證，並發展 16S 全長定序腸道菌檢測及跨物種全基因體定序服務，法說會摘要提到公司規劃擴增第三代定序產能至 12 倍，以支應科研與微生物組市場需求。四、台灣高齡化、癌症預防、慢性病管理、健康臺灣政策與 NGS 癌症檢測健保/補助趨勢，均有利於臨床端滲透。五、LDTS 與精準醫療檢測法規趨嚴會提高實驗室品質、驗證與認證門檻，對具 ISO/TAF、衛福部列冊與臨床合作經驗者有利。主要挑戰包括：基因檢測價格競爭激烈，國內同業與國際品牌透過代理模式進入台灣；Guardant、SomaLogic 等代理產品受原廠供應、授權條件、國際定價與匯率影響；癌症早篩雖市場大，但醫師採用、民眾自費意願、臨床證據、法規核准、保險/健保給付皆會影響放量速度；第三代定序、蛋白質體與多體學技術迭代快，須持續投入設備、人員與認證；公司規模仍小，2025 年雖營收成長但獲利基礎薄，若擴張費用先行，短期 EPS 與現金流可能承壓。公司未公開 2026 至 2028 具體財務預測，因此本段為依公開年報、法說會與產業趨勢的情境分析，不視為財務指引。

Supply Chain

Upstream
  • 台灣安捷倫科技股份有限公司 主要供應商；113 年年報列示 2024 年進貨 59,057 仟元、占進貨淨額 42.18%，供應生物晶片、NGS、CRISPR、即時定量 PCR 等相關產品；台灣子公司未於台股掛牌，母公司 Agilent Technologies 為美國上市公司。
  • 富士軟片醫療產品股份有限公司 主要供應商；113 年年報列示 2024 年進貨 41,373 仟元、占進貨淨額 29.55%；台灣公司未於台股掛牌，屬日本富士軟片集團相關醫療產品供應鏈。
  • Guardant Health, Inc. 癌症液態活檢檢測代理與技術來源，產品包括 Guardant360 與 Guardant360 TissueNext；非台股掛牌，為美國上市公司。
  • SomaLogic／Standard BioTools 相關平台 蛋白質體檢測平台技術來源，公司規劃導入 SomaLogic 蛋白質體技術並建立在地化服務；非台股掛牌。
  • Epigentek Group Inc. 代理產品來源之一，年報列示其 ELISA-like 定量與定性檢測套組及抗體；非台股掛牌。
Downstream
  • 醫學中心與醫療院所 臨床檢測、癌症液態活檢、產前與生殖醫學檢測的主要導入與合作通路；多為醫療法人或公立醫院，非台股掛牌。
  • 生殖醫學中心與婦產科診所 NIPT、產前羊水晶片、胚胎著床前染色體篩檢等服務的終端臨床場景；多數非台股掛牌。
  • 學術研究機構、大學與研究單位 科研服務客戶，需求包括生物晶片、NGS、第三代定序、全外顯子定序、菌相分析、蛋白質體與生物資訊分析；多數非營利或公部門機構，非台股掛牌。
  • 產業研發客戶與藥物/診斷研究團隊 多體學、疾病標記、藥物與診斷研發服務潛在客戶；公開資料未揭露具體名單。

Competitors

  • 訊聯基因數位／創源 4160 台股掛牌公司，從事基因檢測、遺傳醫學、精準健康等相關服務；與威健在臨床基因檢測與 NGS 應用部分重疊。
  • 基米 4195 台股掛牌公司，基因體與生物資訊服務業者；與威健在科研定序、生物資訊與基因檢測服務部分重疊。
  • 慧智 6615 台股上櫃公司，聚焦母胎兒醫學、生殖醫學、遺傳醫學、癌症與臨床基因檢測；與威健在產前、生殖醫學與臨床基因檢測市場競爭。
  • 金萬林-創 6645 台股創新板公司，基因檢測、精準醫學與健康管理服務業者；與威健在精準醫學、NGS、檢測服務與醫療院所合作市場競爭。
  • 訊聯 1784 台股掛牌生技公司，雖主軸包含細胞儲存與再生醫療，但市場常與訊聯基因、慧智等基因/精準醫療題材並列，部分臨床與醫療通路資源具間接競爭或合作關係。
  • 國際基因檢測與液態活檢公司 包括國際定序、液態活檢、癌症早篩與多體學平台業者，常透過代理或合作進入台灣；非台股掛牌或未逐一確認掛牌狀態。
Sources（15）

This company profile is compiled from public sources (annual reports, filings, news and analyst reports), not finlab backtest data; the 2025–2028 outlook contains forward-looking estimates and is for reference only.

Method and limitations

  • All returns use adjusted close (etl:adj_close), already adjusted for dividends and splits.
  • Excess return is measured against the TAIEX total-return index (dividends included).
  • Valuation regime and percentile stats use an expanding own-history window (no future data).
  • Revenue-signal event dates align to the first trading day after the filing deadline, avoiding look-ahead.
  • Event samples may overlap in time; stats describe historical distribution only and are less reliable when samples are few.

This page is historical statistics for educational purposes and is not investment advice. Investing involves risk; past performance does not indicate future results. Assess and bear the risk yourself before trading.